Synlogic Q2 2022 net loss $15.8M; cash $106.8M funds into 2024; three data readouts in H2 2022

SYNLOGIC, INC.

2022-Q2 EPS reported -$0.44 revenue$396,000

Net loss $15.8M ($0.22 per share) vs $14.5M ($0.28) in Q2 2021; revenue $0.2M from Roche IBD collaboration.
Cash, equivalents, and short-term investments $106.8M as of June 30, 2022; projected runway into 2024.
Plan to report Phase 2 PKU data in H2 2022 and start Phase 3 in H1 2023; HCU Phase 1 and EH proof-of-concept data also due H2 2022.
Named SYNB2081 (uric acid-lowering Synthetic Biotic for gout), second candidate from Ginkgo Bioworks partnership.
R&D expenses $12.1M (up from $10.7M) and G&A $4.1M (flat YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.